Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
ASCO 2022: Panel discussion on bladder preservation
Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller
ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )
6 Jun 2022
ASCO 2022: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
6 Jun 2022
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )
6 Jun 2022
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022
Review: Best options in localised prostate cancer
Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizaz...
Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )
4 Jun 2022
Everolimus after surgery can improve outcomes in those with high-risk kidney can...
Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA
Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )
4 Jun 2022
Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )
29 Apr 2022
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022